7 insiders at Elanco Animal Health Incorporated (ELAN) reported open-market stock purchases totaling $1,672,850 in recent weeks, according to filings with the U.S. Securities and Exchange Commission. The largest reported purchase came from Kurzius Lawrence Erik (director), who acquired 40,000 shares at $23.40 on August 20, 2026.
Source: SEC Form 4. Option grants and tax-withholding sales are excluded.
| Date | Insider | Role | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|
| 2026-08-20 | Kurzius Lawrence Erik | director | 40,000 | $23.40 | $935,920 | SEC Form 4 |
| 2026-08-18 | O'Neill Shiv | officer: GC AND CORP SEC | 3,998 | $23.58 | $94,273 | SEC Form 4 |
| 2026-08-12 | Harrington Michael J | director | 5,000 | $21.82 | $109,100 | SEC Form 4 |
| 2026-08-07 | VanHimbergen Robert M | officer: EVP and CFO | 4,200 | $23.08 | $96,926 | SEC Form 4 |
| 2026-08-07 | Herendeen Paul | director | 10,000 | $23.68 | $236,850 | SEC Form 4 |
| 2026-05-15 | Modi Rajeev A. | officer: SEE REMARKS | 4,911 | $20.35 | $99,939 | SEC Form 4 |
| 2026-05-15 | Simmons Jeffrey N | director, officer: PRESIDENT, CEO AND DIRECTOR | 4,971 | $20.09 | $99,843 | SEC Form 4 |
Elanco Animal Health Incorporated is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. It carried a market capitalization of about $12.0B, with shares trading near $23.97.
This article is automated factual reporting of public SEC filings, for informational purposes only. It is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security, and reflects no opinion on the company. Figures are drawn from filings believed reliable but are not guaranteed. Always verify against the primary SEC filing and consult a licensed professional. Investing can lose value, up to total loss.